193 related articles for article (PubMed ID: 19118050)
1. BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.
Litzenburger BC; Kim HJ; Kuiatse I; Carboni JM; Attar RM; Gottardis MM; Fairchild CR; Lee AV
Clin Cancer Res; 2009 Jan; 15(1):226-37. PubMed ID: 19118050
[TBL] [Abstract][Full Text] [Related]
2. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.
Kim HJ; Litzenburger BC; Cui X; Delgado DA; Grabiner BC; Lin X; Lewis MT; Gottardis MM; Wong TW; Attar RM; Carboni JM; Lee AV
Mol Cell Biol; 2007 Apr; 27(8):3165-75. PubMed ID: 17296734
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
[TBL] [Abstract][Full Text] [Related]
4. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
5. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
[TBL] [Abstract][Full Text] [Related]
6. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
8. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
[TBL] [Abstract][Full Text] [Related]
9. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells.
Yanochko GM; Eckhart W
Breast Cancer Res; 2006; 8(2):R18. PubMed ID: 16584539
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
[TBL] [Abstract][Full Text] [Related]
11. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
12. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
[TBL] [Abstract][Full Text] [Related]
13. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
[TBL] [Abstract][Full Text] [Related]
15. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.
Franks SE; Jones RA; Briah R; Murray P; Moorehead RA
BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578
[TBL] [Abstract][Full Text] [Related]
16. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
17. Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini.
Klos KS; Warmka JK; Drachenberg DM; Chang L; Luxton GW; Leung CT; Schwertfeger KL; Wattenberg EV
PLoS One; 2014; 9(3):e90722. PubMed ID: 24599099
[TBL] [Abstract][Full Text] [Related]
18. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M
Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410
[TBL] [Abstract][Full Text] [Related]
19. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
20. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.
Novosyadlyy R; Lann DE; Vijayakumar A; Rowzee A; Lazzarino DA; Fierz Y; Carboni JM; Gottardis MM; Pennisi PA; Molinolo AA; Kurshan N; Mejia W; Santopietro S; Yakar S; Wood TL; LeRoith D
Cancer Res; 2010 Jan; 70(2):741-51. PubMed ID: 20068149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
